Slides to Accompany Artful Prior Art. Derwent GENESEQ Database Collection of patented DNA sequences –10 or more base pairs Coverage from 1981 Feb. 2001:

Slides:



Advertisements
Similar presentations
Patents Under Paris © 2006 David W. Opderbeck. Key Provisions National Treatment National Treatment National Treatment National Treatment Right of Priority.
Advertisements

Patents Under U.S. Law © 2006 David W. Opderbeck.
PATENTS IN BIOTECHNOLOGY presented to the IEEE Engineering in Medicine and Biology Buenaventura Chapter Nicole Ballew Chang, PhD Lauren E. Schneider, Esq.
UNITED STATES PATENT AND TRADEMARK OFFICE A full transcript of this presentation can be found under the Notes Tab. 35 USC 112 (f)*: Identifying Limitations.
Disclaimer: The information provided by the USPTO is meant as an educational resource only and should not be construed as legal advice or written law.
Patent Law and Policy University of Oregon Law School Fall 2009 Elizabeth Tedesco Milesnick Patent Law and Policy, Fall 2009 Class 5, Slide 1.
Combinatorial Technology Supervisory Patent Examiner
William Boshnick Greenblum & Bernstein, P.L.C.
Rule 105 Requirements in Plant Patent Applications Bruce Campell Supervisory Patent Examiner Art Unit
By David W. Hill AIPLA Immediate Past President Partner Finnegan, Henderson, Farabow, Garrett & Dunner, LLP Overview of the America Invents Act.
Incorporation by Reference
June 8, 2006 PATENTS: WHAT YOU SHOULD KNOW Steven R. Ludwig, Ph.D., Esq.
Filing for a United States Patent “Helpful Hints” U.S. Patent and Trademark Office.
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
Utility and Written Description Steve Kunin Deputy Commissioner for Patent Examination Policy Esther Kepplinger Deputy Commissioner for Patent Operations.
INTRODUCTION TO PATENT RIGHTS The Business of Intellectual Property
1 Bioinformatics Practice Considerations October 20, 2011 Ling Zhong, Ph.D.
1 Rule 132 Declarations and Unexpected Results Richard E. Schafer Administrative Patent Judge Board of Patent Appeals and Interferences.
The America Invents Act (AIA) - Rules and Implications of First to File, Prior Art, and Non-obviousness -
“REACH-THROUGH CLAIMS”
1 Biotechnology Partnership Meeting April 17, 2001 James Martinell Senior Level Examiner Technology Center 1600.
Intellectual Property March 4, 2015 Don Keach Director, Intellectual Property Development and Technology Transfer Office Copyright University of Kentucky.
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
1 Single Nucleotide Polymorphisms (SNP) Gary Jones SPE, Technology Center 1600 (703)
Research in the Shadow of DNA Patents Andrew Chin Microarray Workshop April 5, 2002.
Intellectual Property Workshop Patents and WPI’s Policies November 12, 2003 William W. Durgin Associate Provost for Academic Affairs Vice President for.
Introduction to Nonobviousness Patent Law
Intellectual Property Boston College Law School February 27, 2008 Patent - Enablement.
Graham v John Deere Patent Law. Justice Tom Clark ( )
Intellectual Property
Intellectual Property Boston College Law School March 3, 2008 Patent - Nonobviousness.
Patent Overview by Jeff Woller. Why have Patents? Patents make some people rich – but, does that seem like something the government should protect? Do.
Patents 101 April 1, 2002 And now, for something new, useful and not obvious.
Intellectual Property Boston College Law School February 16, 2009 Patent – Novelty.
Intellectual Property Boston College Law School February 14, 2007 Patent - Utility.
® ® From Invention to Start-Up Seminar Series University of Washington The Legal Side of Things Invention Protection Gary S. Kindness Christensen O’Connor.
Lauren MacLanahan Office of Technology Licensing GTRC.
SECTION 101 OF THE PATENT LAW Describes what is patentable subject matter: "Whoever invents or discovers any new and useful process, machine, manufacture,
1 Unity of Invention: Biotech Examples TC1600 Special Program Examiner Julie Burke (571)
1 1 AIPLA Firm Logo American Intellectual Property Law Association Hamilton Beach Brands v. Sunbeam Products: Lessons Learned Naomi Abe Voegtli IP Practice.
© 2010 Hodgson Russ LLP IEEE Southern Area Entrepreneur’s Day Overview Of The Patent Process R. Kent Roberts Hodgson Russ LLP (716)
Stem Cells Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Stem Cells — Origin Examination of Stem Cell Claims — Statutes — Sample Claims.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
1 John Calvert Supervisory Patent Examiner
1 Patent Law in the Age of IoT The Landscape Has Shifted. Are You Prepared? 1 Jeffrey A. Miller, Esq.
PATENTS Elements of Patentability Victor H. Bouganim WCL, American University.
Overcoming Prior Art References Non-Enabling Prior Art References Gary Kunz SPE Art Unit 1616.
Josiah Hernandez Patentability Requirements. Useful Having utilitarian or commercial value Novel No one else has done it before If someone has done it.
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
Patentability of Reach-Through Claims Brian R. Stanton Practice Specialist Technology Center 1600 (703)
New Sections 102 & 103 (b) Conditions for Patentability- (1) IN GENERAL- Section 102 of title 35, United States Code, is amended to read as follows: -`Sec.
Patentability Considerations in the 3-D Structure Arts Patentability Considerations in the 3-D Structure Arts Michael P. Woodward Supervisory Patent Examiner.
Trilateral Project WM4 Report on comparative study on Examination Practice Relating to Single Nucleotide Polymorphisms (SNPs) and Haplotypes. Linda S.
Patents IV Nonobviousness
How to Claim your Biotech- Based Invention Deborah Reynolds Detailee, TCPS
INTERIM GUIDELINES FOR PATENT SUBJECT MATTER ELIGIBILITY ARDIN MARSCHEL SPE AU 1631 (571)
Patentable Subject Matter Donald M. Cameron. 2 Patents: The Bargain Public: gets use of invention after patent expires Inventor/Owner: gets limited monopoly.
© 2008 International Intellectual Property June 16, 2009 Class 2 Introduction to Patents.
Obviousness I Class Notes: February 6, 2003 Law 677 | Patent Law | Spring 2003 Professor Wagner.
1 Utility Guidelines, Homology Claims and Anti-Sense Molecule Claims Drew Hissong, Ph.D. dhissong*sughrue.com Sughrue Mion, PLLC
LYDON - TERMINAL DISCLAIMERS1 Terminal Disclaimer (TD) A Terminal Disclaimer states that the patent –will expire on the same date as a related.
Patents 101 March 28, 2006 And now, for something new, useful and not obvious.
Patents 101 March 28, 2006 And now, for something new, useful and not obvious.
Patents IV Nonobviousness
Global Innovation Management Workout on Writing a Patent
Patentable Subject Matter
Stem Cells Peter Paras, Jr.
03.Legal Requirements for Patentability
BEST PRACTICES for Graduate Students
A tutorial and update on patentable subject matter
Presentation transcript:

Slides to Accompany Artful Prior Art

Derwent GENESEQ Database Collection of patented DNA sequences –10 or more base pairs Coverage from 1981 Feb. 2001: 1,000,000 sequences Feb. 2002: 2,000,000 sequences Oct. 2003: 3,900,000 sequences

U.S. Patent No. 6,074, The purified preparation of claim 1 wherein the oligonucleotide comprises a contiguous sequence of at least 8 nucleotides complementary to either strand of the nucleotide residue sequence depicted in FIG. 62.

Figure 62 Strand A has 9,185 bases, beginning with: 5-CACTCCACCATGAATCACTCCCCTGTG AGGAACTACTGTCTTCACGCAGAAAGCGT CTAG…. Strand B is Strand As reverse complement. Claim covers 18,356 oligonucleotides (minus duplicates) But there are only 4 8 = 65,536 possible oligonucleotides with 8 bases!

What is Patented? An isolated and purified DNA molecule.

Why is it Patentable? Statutory law Case law –Patent Office Guidelines

35 U.S.C. § 101 (1952) Whoever invents or discovers any new and useful process, machine, manufacture, or combination of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

35 U.S.C. § 103 (1952) (a) A patent may not be obtained … if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art … (c) Patentability shall not be negatived by the manner in which the invention was made.

Patent-Defeating Disclosures A patent may not claim subject matter that was described in a printed publication –before the date of invention; or –more than one year before the application filing date. 35 U.S.C. § 102(a)

Some DNA Disclosure Programs Immediate publication of DNA sequences in public databases –Human Genome Project (Genbank) –Merck Gene Index (ESTs) Filing of statutory invention registrations: 35 U.S.C. § 157 –SNP Consortium

Limitations Publication of sequence information does not invalidate claims to subsequences per se Publication of ESTs does not invalidate claims to full-length genes or subsequences thereof –In re Deuel; In re Bell

Another Approach: Quiet Publication Is a doctoral thesis a printed publication under 102(b)? Yes, if it is publicly accessible. In re Hall. General library practice may be relied upon to establish an approximate time for thesis accessibility. Library directors affidavit: The dissertation most probably was available for general use toward the beginning of the month of December, 1977.

In re Hall An applicant has constructive knowledge of all properly indexed, cataloged and shelved library materials worldwide.

Described in a Printed Publication l To anticipate a claim to one or more chemical compounds, a single printed publication must: l specifically describe a compound within the scope of the claim l disclose a method of making the compound that enables one of ordinary skill in the art to do so l recite at least one significant useful property (§ 101 utility requirement need not be met) l It is not necessary that the disclosed compound actually have been made

Previous Work General methods of making and using oligonucleotides of arbitrary sequence are well known and described in the literature. But specific oligonucleotides are not described in this literature, so there is no § 102(a) bar

§ 102(a) Requirements A § 102(a) reference must include: –A specific description of the subject matter and –Instructions that will enable an ordinary practitioner to make and use the subject matter Not necessary to have actually made or used the subject matter A single copy in a public library counts as publication Solution: Describe 11 million DNA sequences, and general methods of making and using them, on a single CD-ROM

The CD-ROM On the Preparation and Utilization of Isolated and Purified Oligonucleotides As described in U.S. Patent No. 5,808,022 (issued Sept. 15, 1998) (William D. Huse), oligonucleotide synthesis proceeds via linear coupling of individual monomers in a stepwise reaction. The reactions are generally performed on a solid phase support...

The CD-ROM Based on the the disclosures herein and the knowledge of a person of ordinary skill in the art, it will be apparent to such a person how to make and use an isolated and/or purified oligonucleotide characterized by any of the following nucleotide sequences:

The CD-ROM 5'-AAACACCC-3' 5'-AAACACCG-3' 5'-AAACACGC-3' 5'-AAACACGG-3' 5'-AAACAGCC-3' 5'-AAACAGCG-3' 5'-AAACAGGC-3' 5'-AAACAGGG-3' 5'-AAACCACC-3'...

Anticipation of Oligonucleotide Patents # of 8-to-12 base oligonucleotides claimed % of possible claims anticipated 149.6% 274.6% 387.2% % %